Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 5/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 5/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837380 | 0.89 | PDE2A (0.40) | PDE2AARSMN1; SMN2 | |
| SCHEMBL836935 | 0.85 | P4HTM (0.37) | — | |
| SCHEMBL837576 | 0.83 | NR3C1 (0.40) | PDE2AARDPP4DPP7NR3C1 | |
| SCHEMBL1414552 | 0.82 | DPP4 (0.34) | PDE2AARDPP4DPP7JAK2 | |
| SCHEMBL837462 | 0.81 | AR (0.35) | PDE2AARDPP4DPP7NR3C1 | |
| SCHEMBL837795 | 0.81 | CNR2 (0.43) | ARMDM2 | |
| SCHEMBL837416 | 0.79 | NR3C2 (0.35) | PDE2AARDPP4DPP7MDM2 | |
| SCHEMBL836906 | 0.78 | MET (0.39) | ARMDM2 | |
| SCHEMBL837617 | 0.77 | PDE2A (0.41) | PDE2AARSMN1; SMN2MDM2 | |
| SCHEMBL837879 | 0.77 | AR (0.34) | PDE2AARNR3C1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | claimed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | claimed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | claimed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | claimed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | claimed |
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | PDE2A 1196/4885AR 71/4885KCNQ3 1824/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | PDE2A 1196/4885AR 71/4885KCNQ3 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.